Physical Resources Core
物理资源核心
基本信息
- 批准号:10475276
- 负责人:
- 金额:$ 82.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-25 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:Active ImmunizationAllelesAnimalsAntibodiesAntibody DiversityAntibody ResponseAntigen-Antibody ComplexAntigensBar CodesBase SequenceBiophysicsCell LineCell Surface ProteinsCellsCellular biologyClinical TrialsCollectionComputing MethodologiesDataData ReportingData SetDevelopmentDisease ProgressionEffector CellEvaluationFc ImmunoglobulinsFc ReceptorFc domainFutureGenerationsGenesGenetic PolymorphismGenetic VariationGenotypeGoalsGoldHIVHIV-1HIV-1 vaccineHaplotypesHumanImmuneImmune responseImmunoglobulin AllotypesImmunologyIn SituIn VitroIndividualInfectionKnowledgeMacaca mulattaMediatingMethodsModelingMonitorMonoclonal AntibodiesOutcomeOutcome StudyPassive ImmunizationPhenotypePopulationProductionProtein IsoformsReagentReceptor GeneRecombinantsRegulationReportingResearch PersonnelResearch Project GrantsResearch SupportResourcesRhesusSamplingSequence AnalysisSerologyServicesSignal TransductionSingle Nucleotide PolymorphismStructureSurveysTestingTherapeuticTranslationsValidationViral AntibodiesViral ProteinsViremiaVirusWorkbaseclinical trial participantdisorder riskexperienceexperimental studyimmunoprophylaxisimprovedin vivoinfection riskinnovationneutralizing antibodynext generation sequencingnoveloutcome predictionprogramsprophylacticprospectiveresponsesimian human immunodeficiency virustooltranscriptometranscriptome sequencingvaccine candidatevaccine strategy
项目摘要
ABSTRACT_Core 1
Fc receptors (FcRs) are cell surface proteins that interact with antibody Fc domains to mediate effector cell
responses that contribute to the antiviral functionality of antibodies. The diversity of antibodies (isotypes,
subclasses, allotypes) and FcRs (types, gene polymorphisms, isoforms) influences antiviral antibody effector
functions by modulating the interactions between antigen–antibody immune complexes and FcRs. However,
the relative combined contributions of these key variables to protective outcomes in human and rhesus
macaque (RM) active and passive immunization studies are unknown. Thus, there is a critical need to
characterize how different antibody isotypes, subclasses, allotypes, and FcR alleles impact species-specific
FcR-dependent antibody effector functions in order to understand how immunoprophylaxis trials conducted in
the RM model can predict outcomes in humans. The overall goal of the Physical Resources Core is to develop
and provide this Program with the tools, reagents, samples, and nucleic acid sequence datasets and analyses
needed for translation of FcR and antibody Fc genetic diversity among humans and RM to phenotypes,
effector functions, and study outcomes. To achieve this, the Physical Resources Core brings together an
innovative team of investigators with extensive experience and expertise in the generation, validation, and
analysis of next-generation sequencing data; and in the development, production, validation, distribution, and
application of novel immunology reagents and materials that are not commercially available. Guided by strong
preliminary data, and using a combination of gold-standard and state-of-the art approaches, the Physical
Resources Core will achieve the objective of supporting Research Projects 1, 2, 3 and the Overall Program
through focus on completion of three Specific Aims:
Aim 1. Quantify human FcR diversity in HIV-1 clinical trial participants.
Aim 2. Define antibody Fc allotype diversity in humans and RM.
Aim 3. Provide immunology reagents and services.
Fulfillment of the aims of the Core will be significant and impactful because it will lead to identification of the
combinations of nAb and nnAb and effector cell biology for improved understanding of in situ functions. This
will provide a roadmap to improve testing accuracy and evaluations of both future active, and
immunoprophylaxis, vaccine candidates in human clinical trials. The Physical Resources Core will help
generate knowledge essential to accomplishing the Overall Goal of this Program: to determine the impact of
antibody allotype and FcR genotype on antiviral outcomes in vitro and in vivo, thus informing how antibody Fc
effector functions can be used to improve antibody-based vaccine strategies, increase the relative antiviral
activity of HIV-1 specific antibody subclasses, and augment broad-neutralizing antibody-based prophylactic
and therapeutic approaches.
摘要_核心1
Fc受体(FcRs)是与抗体Fc结构域相互作用以介导效应细胞增殖的细胞表面蛋白。
有助于抗体的抗病毒功能的应答。抗体的多样性(同种型,
亚类、同种异型)和FcR(类型、基因多态性、同种型)影响抗病毒抗体效应子
通过调节抗原抗体免疫复合物与FcR之间的相互作用来发挥作用。但是,在这方面,
这些关键变量对人类和恒河猴保护性结果的相对综合贡献
猕猴(RM)主动和被动免疫研究是未知的。因此,迫切需要
表征不同的抗体同种型、亚类、同种异型和FcR等位基因如何影响物种特异性
FcR依赖性抗体效应子的功能,以了解如何进行免疫预防试验,
RM模型可以预测人类的结果。物理资源核心的总体目标是开发
并向本计划提供工具、试剂、样本和核酸序列数据集和分析
人类和RM中的FcR和抗体Fc遗传多样性转化为表型所需的,
效应器功能和研究结果。为了实现这一目标,物理资源核心汇集了
创新的研究团队,在生成、验证和
分析下一代测序数据;以及在开发、生产、验证、分销和
新的免疫学试剂和材料的应用是不可商购的。以强为导
初步数据,并使用金本位和最先进的方法相结合,物理
核心资源将实现支持研究项目1、2、3和整体计划的目标
通过重点完成三个具体目标:
目标1。量化HIV-1临床试验参与者中的人类FcR多样性。
目标2.定义人类和RM中抗体Fc同种异型多样性。
目标3.提供免疫学试剂和服务。
实现《核心文件》的目标将具有重要意义和影响力,因为它将导致确定
nAb和nnAb与效应细胞生物学的组合用于改善对原位功能的理解。这
将提供一个路线图,以提高测试的准确性和评估未来的活动,
免疫预防,人类临床试验中的候选疫苗。物理资源核心将帮助
产生实现本计划总体目标所必需的知识:确定
抗体同种异型和FcR基因型对体外和体内抗病毒结果的影响,从而告知抗体Fc
效应子功能可用于改进基于抗体的疫苗策略,增加相对抗病毒性,
HIV-1特异性抗体亚类的活性,并增强基于广泛中和抗体的预防性
和治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Justin Joseph Pollara其他文献
Justin Joseph Pollara的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Justin Joseph Pollara', 18)}}的其他基金
Combined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigens
联合乙型肝炎和 HIV-1 包膜疫苗接种,通过对不相关抗原的关联识别来增强 T 细胞的帮助
- 批准号:
9764517 - 财政年份:2017
- 资助金额:
$ 82.27万 - 项目类别:
Combined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigens
联合乙型肝炎和 HIV-1 包膜疫苗接种,通过对不相关抗原的关联识别来增强 T 细胞的帮助
- 批准号:
9412004 - 财政年份:2017
- 资助金额:
$ 82.27万 - 项目类别:
Dual-Affinity Re-Targeting Proteins for Cure of Newborn Infant HIV-1 Infection
双亲和力重新靶向蛋白治疗新生儿 HIV-1 感染
- 批准号:
9203119 - 财政年份:2016
- 资助金额:
$ 82.27万 - 项目类别:
Dual-Affinity Re-Targeting Proteins for Cure of Newborn Infant HIV-1 Infection
双亲和力重新靶向蛋白治疗新生儿 HIV-1 感染
- 批准号:
9308869 - 财政年份:2016
- 资助金额:
$ 82.27万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 82.27万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 82.27万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 82.27万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 82.27万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 82.27万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 82.27万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 82.27万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 82.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 82.27万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 82.27万 - 项目类别: